ipilimumab N01

DRUG4 trials

Sponsors

Sun Yat-sen University, Tianjin Medical University Cancer Institute and Hospital, Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.

Conditions

BRAF V600ECetuximabColorectal CancerConversion TherapyDabrafenibHCC - Hepatocellular CarcinomaHepato Cellular Carcinoma (HCC)Ipilimumab N01

Phase 2

TACE or Ablation Combined With Sintilimab and Ipilimumab N01 as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma With Intermediate-High Recurrence Risk

Not yet recruitingNCT07487662

Sun Yat-sen UniversityHepato Cellular Carcinoma (HCC)

Start: 2026-03-18End: 2028-03-17Target: 105Updated: 2026-03-27

A Phase II Study of Sintilimab Combined With Ipilimumab N01, Cetuximab and Dabrafenib in Patients With Microsatellite-Stable, BRAF V600E-Mutated Metastatic Colorectal Cancer

RecruitingNCT07506109

Tianjin Medical University Cancer Institute and HospitalBRAF V600E, Cetuximab, Colorectal Cancer +4

Start: 2026-03-01End: 2028-06-01Target: 49Updated: 2026-04-07

Ipilimumab N01 Combined With Sintilimab, Bevacizumab Biosimilar, and Hepatic Arterial Infusion Chemotherapy as Conversion Therapy for Unresectable Intermediate-Advanced Hepatocellular Carcinoma

RecruitingNCT07560488

Tianjin Medical University Cancer Institute and HospitalConversion Therapy, HCC - Hepatocellular Carcinoma

Start: 2026-03-30End: 2028-04-01Target: 43Updated: 2026-05-01

Neoadjuvant and Adjuvant Therapy Studies of Sintilimab Combined With Chemotherapy With or Without Ipilimumab N01 in Resectable Gastric/Gastroesophageal Junction Adenocarcinoma

Not yet recruitingNCT07643623

Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.Resectable Gastric/Gastroesophageal Junction Adenocarcinoma

Start: 2026-06-15End: 2031-12-31Target: 720Updated: 2026-06-11